Spectral Medical Announces Second Quarter Results

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Spectral Medical Inc., (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2020.

Financial Review

Revenue for the three months ended June 30, 2020 was $517,000 compared to $1,041,000 for the same three-month period last year. For the six-months ended June 30, 2020, revenue was $1,148,000 compared to $1,588,000 in the first half of 2019. The majority of the decrease is due to the timing of orders for product revenue and the non-recurring technology transfer revenue. This was mitigated by an increase in royalty revenue, and revenue from the exclusive distribution agreement with Baxter International Inc. (“Baxter”).

Operating costs for the quarter-ended June 30, 2020, were $2,466,000 compared to $2,093,000 for the corresponding period in 2019. Operating costs for the six-months ended June 30, 2020 were $6,522,000, an increase of $2,889,000 from $3,633,000 for the six-month period ended June 30, 2019. The increase is a result of the ramping up of the Company’s Phase III clinical trial, whereby costs vary depending on the timing and level of patient enrolment. In addition, there was an increase in share compensation expense, due to options being granted earlier in 2020 that had higher share option valuations compared to the share option valuation for share options issued in 2019. Salaries and benefits also increased by approximately $189,000 for the six-months ended June 30, 2020 due to the addition of the Company’s CFO, who joined in August, 2019. Furthermore,  as previously stated, the Company incurred one-time costs associated with a legacy financial advisory services agreement relating to the commercial transaction agreement completed with Baxter and the withdrawn prospectus offering in March 2020. Lastly, there was a 4% decline in the CAD/USD exchange rate in the period from March 31, 2020 to June 30, 2020, which resulted in a foreign exchange loss in the second quarter, reversing the foreign exchange gain recorded in the first quarter of 2020. The CAD/USD exchange rate was relatively consistent throughout 2019.

The Company continues to maintain a low cost operating structure for its base business operations.

For the three-months ended June 30, 2020, the Company reported a loss of $1,949,000 ($0.009 loss per share) compared to a loss of $1,052,000 ($0.005 loss per share) for the three-months ended June 30, 2019. Loss for the six-months ended June 30, 2020 was $5,374,000 ($0.024 loss per share) compared to a loss of $2,045,000 ($0.009 loss per share) for the same period last year.

The Company concluded the second quarter of 2020 with cash of $10,230,000 compared to $1,435,000 cash on hand as of December 31, 2019. This cash balance reflects the non-refundable US$5,000,000 (CA$6,629,000) upfront rights payment from Baxter, which was received in the first quarter, as well as the net proceeds of $4,397,000 received on the public offering, reduced by operating cash outflows.  Based on current operating plans, Spectral expects to have cash to fund its 2020 business plan.

The total number of common shares outstanding for the Company was 236,605,745 as at June 30, 2020.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.